Literature DB >> 3349495

Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile.

E A Lien1, E Solheim, S Kvinnsland, P M Ueland.   

Abstract

The occurrence of tamoxifen metabolites in bile was investigated in a 57-year-old female patient receiving chronic treatment with tamoxifen. In bile treated with beta-glucuronidase, two major peaks were detected using a chromatographic system developed for the quantitation of tamoxifen metabolites in human serum. One sharp peak coeluted with 4-hydroxy-tamoxifen whereas a second broad peak eluted slightly ahead of tamoxifen and was separated from all major serum metabolites. This latter peak was identified as the cis (about 30%) and trans (about 70%) isomers of 4-hydroxy-N-desmethyltamoxifen. The identification was based on (a) coelution with authentic standard on reversed-phase chromatography and formation of fluorescent material after photoactivation, (b) a molecular ion (M + 1)+ of 374 m/z as determined with liquid chromatography-mass spectrometry, and (c) a fragmentogram identical to that of the authentic standard, as obtained by gas chromatography-mass spectrometry.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3349495

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.

Authors:  D de Vos; P H Slee; D Stevenson; R J Briggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 3.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

4.  Germline pharmacogenetics of tamoxifen response: have we learned enough?

Authors:  Zeruesenay Desta; David A Flockhart
Journal:  J Clin Oncol       Date:  2007-11-20       Impact factor: 44.544

5.  Electrospray ionization mass spectrometry for analysis of low-molecular-weight anticancer drugs and their analogues.

Authors:  G K Poon; G M Bisset; P Mistry
Journal:  J Am Soc Mass Spectrom       Date:  1993-07       Impact factor: 3.109

6.  Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.

Authors:  N T Brewer; J T Defrank; W K Chiu; J G Ibrahim; C M Walko; P Rubin; O A Olajide; S G Moore; R E Raab; D R Carrizosa; S W Corso; G Schwartz; J M Peppercorn; H L McLeod; L A Carey; W J Irvin
Journal:  Public Health Genomics       Date:  2014-01-22       Impact factor: 2.000

Review 7.  Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy.

Authors:  Deirdre P Cronin-Fenton; Per Damkier; Timothy L Lash
Journal:  Future Oncol       Date:  2014-01       Impact factor: 3.404

Review 8.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

9.  Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators.

Authors:  Carolyn D DuSell; Erik R Nelson; Bryan M Wittmann; Jackie A Fretz; Dmitri Kazmin; Russell S Thomas; J Wesley Pike; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2009-11-09

Review 10.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.